<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964557</url>
  </required_header>
  <id_info>
    <org_study_id>D7990C00004</org_study_id>
    <nct_id>NCT04964557</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia</brief_title>
  <acronym>SOLANO</acronym>
  <official_title>A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study&#xD;
      aims to evaluate safety, efficacy and tolerability of AZD8233.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized parallel, double-blind, placebo-controlled Phase 2b study in&#xD;
      approximately 376 participants with hyperlipidaemia. The primary objective of the study is to&#xD;
      assess the safety and tolerability of AZD8233 as compared with placebo, and the effect of&#xD;
      AZD8233 versus placebo on relative change in LDL-C. The study will be conducted at up to 100&#xD;
      sites in up to 8 countries.&#xD;
&#xD;
      The screening period starts up to 28 days before the randomization visit and ends on Day -1.&#xD;
      Eligible participants will attend 1 enrollment visit and 15 visits during the treatment&#xD;
      period and 2 additional visits during the safety follow up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline on serum LDL-C</measure>
    <time_frame>From baseline to Day 197</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in PCSK9</measure>
    <time_frame>From baseline to Day197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of AZD8233</measure>
    <time_frame>Day 29, Day 85, Day 99, Day 141, Day 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADAs) during the treatment period and follow-up period</measure>
    <time_frame>Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 281</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141, Day 155, Day 169, Day 183, Day 197, Day 225, Day 281</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with an ECG determined to be abnormal and clinically significant</measure>
    <time_frame>Day 1, Day 85, Day 169, Day 225, Day 281</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital sign: Pulse rate</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225, Day 281</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital sign: Blood pressure</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225, Day 281</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital sign: Temperature</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225, Day 281</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with clinically significant hematology and/or clinical chemistry parameters as defined by AEs</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225, Day 281</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Hyperlipidaemia</condition>
  <arm_group>
    <arm_group_label>AZD8233</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8233 for subcutaneous use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution for subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8233</intervention_name>
    <description>PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.</description>
    <arm_group_label>AZD8233</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 75 years of age, inclusive, at the time of signing the&#xD;
             informed consent&#xD;
&#xD;
          -  Participants who have a fasting LDL-C ≥ 70 mg/dL (1.8 mmol/L) but &lt; 190 mg/dL (4.9&#xD;
             mmol/L) at screening&#xD;
&#xD;
          -  Participants who have fasting triglycerides &lt; 400 mg/dL (&lt; 4.52 mmol/L) at screening&#xD;
&#xD;
          -  Participants are receiving a stable dose (≥ 3 months) of maximally tolerated statin&#xD;
             and/or ezetimibe therapy&#xD;
&#xD;
          -  Male or female of non-childbearing potential&#xD;
&#xD;
          -  Signed and dated written informed consent prior to any mandatory study specific&#xD;
             procedures, sampling, and analyses&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  eGFR &lt; 40 mL/min/1.73m2 using the CKD-EPI&#xD;
&#xD;
          -  History or presence of gastrointestinal, hepatic or renal disease or any other&#xD;
             conditions known to interfere with absorption, distribution, metabolism or excretion&#xD;
             of drugs&#xD;
&#xD;
          -  Any uncontrolled or serious disease, or any medical (eg,. known major active infection&#xD;
             or major haematological, renal, metabolic, gastrointestinal or endocrine dysfunction)&#xD;
             or surgical condition that, in the opinion of the investigator, may either interfere&#xD;
             with participation in the clinical study and/or put the participant at significant&#xD;
             risk (according to the investigator's judgment) if he/she participates in the clinical&#xD;
             study&#xD;
&#xD;
          -  Poorly controlled T2DM, defined as HbA1c &gt; 10%&#xD;
&#xD;
          -  Acute ischaemic cardiovascular events including stroke within 30 days, or heart&#xD;
             failure with New York Heart Association (NYHA) Class III to IV&#xD;
&#xD;
          -  Blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic&#xD;
             purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of&#xD;
             bleeding (frequent bleeding gums or nose bleeds)&#xD;
&#xD;
          -  High-risk of bleeding diathesis or anti-platelet therapy other than low dose aspirin&#xD;
             (≤100mg/day).&#xD;
&#xD;
          -  Malignancy within the last 10 years&#xD;
&#xD;
          -  Recipient of any major organ transplant&#xD;
&#xD;
          -  LDL or plasma apheresis within 12 months prior to randomisation&#xD;
&#xD;
          -  Uncontrolled hypertension defined as average supine SBP &gt; 160 mmHg or DBP &gt; 90 mmHg&#xD;
&#xD;
          -  Heart rate after 10 minutes supine rest &lt; 50 or &gt; 100 bpm&#xD;
&#xD;
          -  Any laboratory values with the following deviations at the Screening Visit; test may&#xD;
             be repeated at the discretion of the investigator if abnormal:&#xD;
&#xD;
               -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis&#xD;
                  C antibody, and human immunodeficiency virus (HIV)&#xD;
&#xD;
               -  ALT &gt; 1.5 × ULN&#xD;
&#xD;
               -  AST &gt; 1.5 × ULN&#xD;
&#xD;
               -  TBL &gt; ULN&#xD;
&#xD;
               -  ALP &gt; 1.5 × ULN&#xD;
&#xD;
               -  WBC &lt; lower limit of normal (LLN).&#xD;
&#xD;
               -  Haemoglobin &lt; 12 g/dL in males or &lt; 11 g/dL in females&#xD;
&#xD;
               -  Platelet count ≤ LLN&#xD;
&#xD;
               -  aPTT &gt; ULN or Prothrombin Time &gt; ULN&#xD;
&#xD;
               -  UACR &gt; 11 mg/mmol (100 mg/g)&#xD;
&#xD;
               -  UPCR &gt; 300 mg/g&#xD;
&#xD;
          -  Any clinically important abnormalities in rhythm, conduction or morphology of the&#xD;
             resting ECG and any clinically important abnormalities in the 12-lead ECG&#xD;
&#xD;
          -  QTcF &gt; 470 ms; high degree atrioventricular (AV)-block grade II-III and sinus node&#xD;
             dysfunction with significant sinus pause untreated with pacemaker; and cardiac&#xD;
             tachyarrhythmias&#xD;
&#xD;
          -  History of drug and/or alcohol abuse or a positive screen for drugs of abuse&#xD;
&#xD;
          -  Use of warfarin, direct or indirect thrombin inhibitors or factor Xa inhibitors&#xD;
&#xD;
          -  Mipomersen, or lomitapide within 12 months prior to randomisation&#xD;
&#xD;
          -  Any fibrate therapy other than fenofibrate; if the participant is on fenofibrate&#xD;
             therapy, the dose should be stable for at least 6 weeks prior to randomisation&#xD;
&#xD;
          -  Previous administration of AZD8233/AZD6615) or inclisiran (LEQVIO ® Novartis)&#xD;
&#xD;
          -  Use of evolocumab (REPATHA® Amgen) and alirocumab (PRALUENT® Regeneron) within 3&#xD;
             months of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stow</city>
        <state>Ohio</state>
        <zip>44224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <zip>23435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Benesov</city>
        <zip>256 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>603 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaromer</city>
        <zip>551 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liberec 2</city>
        <zip>460 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louny</city>
        <zip>440 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Dubina</city>
        <zip>700 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pribram</city>
        <zip>261 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Svendborg</city>
        <zip>5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Békéscsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orosháza</city>
        <zip>5900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doetinchem</city>
        <zip>7009 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harderwijk</city>
        <zip>3844 DG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chrzanów</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-082</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Śląska</city>
        <zip>41-710</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wierzchosławice</city>
        <zip>33-122</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>91-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brezno</city>
        <zip>977 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roznava</city>
        <zip>048 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trebišov</city>
        <zip>7501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ferrol</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD8233</keyword>
  <keyword>Efficacy</keyword>
  <keyword>PK</keyword>
  <keyword>PD</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

